Flow-Mediated Dilatation in the Assessment of Coronary Heart Disease: A Meta-Analysis

Xiaoyong Xiao,1 Xiang Li,2 Xiaohua Xiao,3 Jingjing Wang,1 Dehong Liu,1 and Zhe Deng1

1Department of Emergency, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China
2Department of Ultrasound, Shenzhen Pingle Orthopaedic Hospital, Shenzhen 518000, China
3Department of Geriatric Medicine, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China

Received 17 June 2022; Accepted 3 August 2022; Published 28 September 2022

Copyright © 2022 Xiaoyong Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Endothelial dysfunction may contribute to the increased morbidity and mortality associated with coronary heart disease (CHD). Flow-mediated dilatation (FMD) is the most popular noninvasive method for vascular endothelial function evaluation. This meta-analysis aimed to investigate the association between FMD and CHD. We searched the publications listed in the PubMed, Web of Science, Scopus, and Embase databases. Stata 14 software was used to analyze the data. Standardized mean difference (SMD) was used to calculate FMD levels, and the effect sizes were expressed with a 95% confidence interval (CI). I² statistics were used to evaluate statistical heterogeneity. In this meta-analysis, 9 studies enrolled a total number of 943 participants, including 534 (56.63%) patients with CHD and 409 controls (43.37%). We found that patients with CHD showed a significantly lower FMD than the controls (SMD −0.706%; 95% CI: −0.985, −0.427; P = 0.001) with high heterogeneity. In addition, funnel plot analysis suggested asymmetry that could be evidence of publication bias. But sensitivity analyses show that there were no influential studies. This meta-analysis provides evidence that patients with CHD show a significantly lower FMD than controls and highlights the literature on FMD as a hallmark in CHD diseases.

1. Introduction

The vascular endothelium plays an essential role in various pathological and physiological processes, for instance, regulating vascular homeostasis, vasoconstriction and dilation, thrombosis, fibrinolysis, inhibition of inflammation, and smooth muscle cell function [1]. An imbalance between the magnitude of injury and the repair capacity of the endothelium is a key factor in the occurrence and development of various cardiovascular diseases, such as myocardial infarction, stroke, and hypertension [2]. Accumulating evidence has confirmed that endothelial dysfunction is considered an important pathological feature of early atherosclerosis [3]. Endothelial function deteriorates during the natural history of cardiovascular diseases, suggesting that it may be a potential biomarker in the context of this disease and warrants further investigation [4]. Therefore, early detection of vascular endothelial dysfunction, timely intervention, and guided treatment are significant for maintaining cardiovascular health and reducing morbidity and mortality associated with cardiovascular diseases and medical costs [5].

Currently, invasive and noninvasive methods are commonly used to evaluate vascular function. Invasive tests require the injection of acetylcholine into human coronary arteries, but their clinical application is limited because they are invasive, time-consuming, and expensive, and they are not recommended for healthy or asymptomatic patients [5]. The noninvasive endothelial function detection method first appeared in the 1990s. With the continuous development of basic and clinical research, the medical industry has paid
increasing attention to examining endothelial function in cardiovascular diseases, and noninvasive vascular endothelial function detection has become a research hotspot [6]. At present, brachial artery flow-mediated dilatation (FMD) is the most popular method for evaluating vascular endothelial function evaluation [7]. It has the advantages of less or no trauma, relatively low cost, simple operation, good repeatability, and wide application and is more acceptable [7]. Therefore, FMD detection has been widely adopted in cardiovascular research in clinical trials.

Many large prospective cohort studies have accepted FMD as an adjunctive marker of coronary heart disease (CHD). Several studies found that a decreased FMD could increase the risk of CHD [8, 9]. However, some of these studies have been summarized in qualitative reviews. Therefore, we conducted a meta-analysis that aims to describe FMD as a potential biomarker for CHD.

2. Methods

2.1. Search Strategy. This meta-analysis followed the guidelines of the preferred reporting items. We searched the publications listed in the electronic databases MEDLINE (source PubMed, January 1, 2001, to January 1, 2021) and Embase (January 1, 2001, to January 1, 2021) using the following text and keywords in combination both as MeSH terms and text word: “flow-mediated dilatation” and “coronary artery disease” or “coronary heart disease” or “coronary vascular disease.”

2.2. Study Inclusion/Exclusion Criteria. Inclusion criteria of this study were as follows: patients with coronary heart disease; FMD brachial artery in CHD and control was detected by high-resolution ultrasound methods, and the brachial artery FMD was calculated as [(reactive hyperemia diameter of the brachial artery-baseline diameter)/baseline diameter × 100%]; and the enrolled studies were prospectively or retrospectively designed. Exclusion criteria were as follows: patients with infections, tumors, and immune disease; incomplete FMD data; literature that was duplicated and poorly designed; and reviews.

2.3. Search and Screening. Two investigators independently screened the titles and abstracts of the studies and excluded those that did not meet the inclusion criteria. After screening the full text, the studies that met the requirements were selected according to the inclusion and exclusion criteria. If two authors had objections to the extracted literature, a third investigator was invited to arrive at the final conclusion. Finally, the articles were written according to the systematic reviews and meta-analyses guidelines.

2.4. Data Analysis and Statistical Methods. Stata 14 software was used to analyze the data. Standardized mean difference (SMD) was used to calculate FMD levels, and the effect sizes were expressed with a 95% confidence interval (CI). Chi-square Cochran’s Q test and the I^2 statistic were used to assess the heterogeneity between studies. In detail, if there was no heterogeneity (I^2 < 50%, P > 0.05), the fixed-effects model was used for analysis. If heterogeneity existed (I^2 ≥ 50%, P ≤ 0.05), the random-effects model was used for analysis. Sensitivity analysis was conducted to determine the stability and credibility of the results. Funnel plots and shear complement methods were used to detect publication biases.

3. Results

3.1. Literature Results. The results of the literature search are shown in Figure 1. After reviewing the titles and abstracts, we retrieved 219 unique citations and eliminated 175. Of the 44 full manuscripts retrieved, 35 were excluded because 12 were reviews, 10 were cross-sectional studies, 5 had no controls, 3 had no data on FMD, 3 did not have enough data on FMD, and 2 were repeat studies. Ultimately, 9 articles were included in the meta-analysis [10–18].

3.2. Study Characteristics. All included studies were observational and were prospectively designed. As shown in Table 1, 9 studies used ultrasound-based FMD to determine the endothelial function in this meta-analysis. A total of 943 participants were included: 534 patients with coronary heart disease (56.63%) and 409 controls (43.37%). Most controls were healthy. The study population is mainly European and Asian. The mean age for the entire study population was 58 years, and males represent 75.59% of them. Most patients in the control group were healthy (Table 1).

3.3. Endothelial Function Assessment in Cardiovascular Diseases. In 9 studies, heterogeneity was I^2 = 71.2% and P = 0.001, suggesting heterogeneity was statistically significant among these studies. Therefore, a random-effects
model was used to analyze the data in this meta-analysis. As shown in Figure 2, we found that the 534 coronary heart disease patients showed a significantly lower FMD than the 409 controls (MD $-0.690\%$; 95% CI: $-0.981$, $-0.398$; $P = 0.001$), suggesting that endothelial dysfunction correlates with coronary heart diseases.

### 3.4. Publication Bias

Publication bias was assessed using a funnel plot analysis. As shown in Figure 3, funnel plot analysis confirmed the existence of significant publication bias, suggesting that publication bias was present in this meta-analysis. Thus, we used the trim and fill method to correct the funnel asymmetry caused by publication bias, and we obtained a similar SMD, indicating that although there was a certain publication bias, the results were stable and reliable. As shown in Figure 4, a sensitivity analysis was performed by culling the included studies one by one, and the SMD was reweighed to evaluate the stability of the results. Similarly, there was a significant difference in FMD between patients with CHD and control, indicating stable results.
4. Discussion

Endothelial cell damage and dysfunction play an important role in developing the process [3]. Studies have shown that arteriosclerosis is related to CHD and can increase the risk of cardiovascular disease [19, 20]. In recent clinical studies, FMD, an accepted method for noninvasive assessment of systemic endothelial function, has been extensively examined [21]. Accumulating evidence indicates that FMD is a hallmark of CHD [10–18]. However, few reviews have summarized the relationship between endothelial function and CHDs. In this study, we systematically reviewed the scientific literature and assessed the differences in endothelial function between the CHD and control groups.

The present meta-analysis results consistently showed that CHDs might be associated with endothelial dysfunction, as evaluated by ultrasound-based FMD of the brachial artery. In particular, we demonstrated that 534 patients with CHD showed a significantly lower FMD than the 409 controls (SMD $-0.690\%$; 95% CI: $-0.981$, $-0.398$; $P < 0.001$), indicating that patients with CHD show a reduced vasodilatory response and endothelial function. Therefore, evaluation of FMD can be a useful noninvasive diagnostic tool for CHD risk assessment.

Many cardiovascular risk factors affect endothelial function, such as race, age, estrogen, hypertension, diabetes, and smoking [22]. Although most patients with CHD have a history of smoking, the relationship between FMD and CHD...
appears to be more complex, and smoking habits may not fully explain the decline in FMD of CHD in this clinical setting.

The funnel plot analysis confirmed the existence of significant publication bias. However, we obtained a similar SMD by the trim and fill method, and there was no obvious difference compared with previous results, possibly because of low power due to the small number of studies [23]. In addition, we obtained the stability of the results in this meta-analysis, which was evaluated by sensitivity analysis. Therefore, we conclude that the results were stable and reliable.

Accumulating evidence indicates that early endothelial dysfunction is a reversible disorder, and several interventions, such as exercise and bilirubin or other medicine, can increase endothelial function and reduce CVD risk [24, 25]. If FMD is taken to be an early marker for CHD, vascular endothelial dysfunction will be evaluated early. Timely intervention and guided treatment can reverse endothelial dysfunction and reduce the morbidity and mortality associated with CHD.

Some potential limitations of our study must be discussed. First, there was a publication bias in this meta-analysis. However, the combined SMD was consistent with the uncut and complemented conclusions, indicating that although there was a certain publication bias, the results were stable and reliable. Second, heterogeneity among the studies was generally significant, and it was not possible to conclusively ascertain sources of heterogeneity. Finally, the small number of studies and participants limited the accuracy of the results. Further efforts will be made to conduct further studies in the future.

5. Conclusion

In conclusion, this meta-analysis provides evidence that patients with CHD show a significantly lower FMD than controls and highlights the literature on FMD as a hallmark in CHD diseases. Although limited in number, these studies provide important evidence that FMD should be considered a worthy biomarker for assessment in future research.

Data Availability

The data used to support the findings of this study are available from the corresponding author or the first author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Zhe Deng and Dehong Liu designed the study. Xiaoyong Xiao, Jingjing Wang, and Xiang Li analyzed the data, plotted the figures, and wrote the manuscript. Xiaohua Xiao was responsible for funding acquisition. All authors read and approved the final manuscript. Xiaoyong Xiao, Xian Li, Xiaohua Xiao, and Jingjing Wang contributed equally to this work.

Acknowledgments

This study was funded by the Shenzhen Key Basic Research Project (KCXFZ20201221173213036).

References

[1] C. Sturtzel, “Endothelial cells,” Advances in Experimental Medicine and Biology, vol. 1003, pp. 71–91, 2017.
[2] M. A. García-Cardeña and G. García-Cardeña, “Endothelial cell dysfunction and the pathobiology of atherosclerosis,” Circulation Research, vol. 118, no. 4, pp. 620–636, 2016.
[3] A. Genis, A. Lochner, and M. Mudau, “Endothelial dysfunction: the early predictor of atherosclerosis,” Cardiovascular Journal of Africa, vol. 4, no. 23, pp. 222–231, 2012.
[4] K. Bellamkonda, M. Williams, A. Handa, and R. Lee, “Flow mediated dilatation as a biomarker in vascular surgery research,” Journal of Atherosclerosis and Thrombosis, vol. 24, no. 8, pp. 779–787, 2017.
[5] P. C. Evans, “Endothelial function in cardiovascular medicine: a consensus paper of the European society of cardiology working groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis,” Cardiovascular Research, vol. 117, pp. 29–42, 2021.
[6] E. S. Varaki, “Peripheral vascular disease assessment in the lower limb: a review of current and emerging non-invasive diagnostic methods,” BioMedical Engineering OnLine, vol. 1, no. 17, p. 61, 2018.
[7] C. C. M. van Mil, A. Greylng, P. L. Zock et al., “Impact of volunteer-related and methodology-related factors on the reproducibility of brachial artery flow-mediated vasodilation,” Journal of Hypertension, vol. 34, no. 9, pp. 1738–1745, 2016.
[8] G. Mathieu, J. Martin, and C. T. Jean, “Cardiometabolic and traditional cardiovascular risk factors and their potential impact on macrovascular and microvascular function: preliminary data,” Clin Hemorheol Microcirc, vol. 59, no. 1, pp. 53–65, 2015.
[9] R. Khan, N. G. Boyes, and M. S. Luchkanych, “Effect of acute isometric handgrip exercise on vascular function in children with congenital heart disease,” Faseb Journal, vol. 21, no. 2, pp. 16–19, 2021.
[10] M. Kazmierski, A. Michalewska-Wludarczyk, and L. J. Krzych, “Intima-media thickness and flow-mediated dilatation in the diagnosis of coronary artery disease in perimenopausal women,” Pol Arch Med Wewn, vol. 120, no. 5, pp. 181–188, 2010.
[11] S. Park, S. Han, S. W. Kim, S. H. Jo, S.-A. Kim, and S. W. Suh, “Association between intra-arterial invasive central and peripheral blood pressure and endothelial function (assessed by flow-mediated dilatation) in stable coronary artery disease,” American Journal of Hypertension, vol. 32, no. 10, pp. 953–959, 2019.
[12] Y. Okura, M. Takao, B. Zhang, Y. Nakashima, and K. Saku, “Cardiovascular risk factor profiles and endothelial function in coronary artery disease patients treated with statins,” Hypertension Research, vol. 27, no. 10, pp. 723–729, 2004.
[13] S. Kozlov, T. Balachonova, H. Machmudova et al., “Carotid atherosclerosis, endothelial dysfunction, and arterial stiffness in young and middle-aged men with coronary artery disease,” International Journal of Vascular Medicine, vol. 2012, pp. 950130, 2012.
[14] I. Altun, F. Oz, S. C. Arkaya et al., “Effect of statins on endothelial function in patients with acute coronary syndrome: a prospective study using adhesion molecules and flow-mediated dilatation,” *Journal of Clinical Medicine Research*, vol. 6, no. 5, pp. 354–361, 2014.

[15] A. Nigam, G. F. Mitchell, J. Lambert, and J.-C. Tardif, “Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease,” *The American Journal of Cardiology*, vol. 92, no. 4, pp. 395–399, 2003.

[16] S. M. Shechter, I. Marai, S. Marai et al., “The association of endothelial dysfunction and cardiovascular events in healthy subjects and patients with cardiovascular disease,” *The Israel Medical Association Journal: IMAJ*, vol. 9, no. 4, pp. 271–276, 2007.

[17] R. Hu, W. S. Siu, W. Q. Lau, C.-P. Wang, H.-F. Lau, and H.-F. Tse, “Impaired nitrate-mediated dilatation could reflect nitrate tolerance in patients with coronary artery disease,” *International Journal of Cardiology*, vol. 120, no. 3, pp. 351–356, 2007.

[18] S. Agewall, L. Henareh, and K. Kublickiene, “Endothelial function in conduit and resistance arteries in men with coronary disease,” *Atherosclerosis*, vol. 184, no. 1, pp. 130–136, 2006.

[19] R. S. Vasan, S. Pan, M. G. Larson, G. F. Mitchell, and V. Xanthakis, “Arteriosclerosis, atherosclerosis, and cardiovascular health: joint relations to the incidence of cardiovascular disease,” *Hypertension*, vol. 78, no. 5, pp. 1232–1240, 2021.

[20] J. Frostegård, “Immunity, atherosclerosis and cardiovascular disease,” *BMC Medicine*, vol. 11, p. 117, 2013.

[21] Y. Luo, Z. Huang, J. Liao et al., “Downregulated GTCPH I/ BH4 pathway and decreased function of circulating endothelial progenitor cells and their relationship with endothelial dysfunction in overweight postmenopausal women,” *Stem Cells International*, vol. 2018, p. 4756263, 2018.

[22] A. W. Vaes, M. A. Spruit, T. Theunis et al., “Endothelial function in patients with chronic obstructive pulmonary disease: a systematic review of studies using flow mediated dilatation,” *Expert Review of Respiratory Medicine*, vol. 11, no. 12, pp. 1021–1031, 2017.

[23] H. Ren, J. Wang, Y. Gao, F. Yang, and W. Huang, “Metabolic syndrome and liver-related events: a systematic review and meta-analysis,” *BMC Endocrine Disorders*, vol. 19, no. 1, p. 40, 2019.

[24] B. J. Parmenter, G. Dieberg, and N. A. Smart, “Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis,” *Sports Medicine*, vol. 45, no. 2, pp. 231–244, 2015.

[25] T. Maruhashi, Y. Kihara, and Y. Higashi, “Bilirubin and endothelial function,” *Journal of Atherosclerosis and Thrombosis*, vol. 26, no. 8, pp. 688–696, 2019.